Cargando…

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects

Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the current superheroes of immunotherapy, unleashing a patient’s own immune cells to kill tumors and revolutionizing cancer treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Remy, Al-Khadairi, Ghaneya, Decock, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947906/
https://www.ncbi.nlm.nih.gov/pubmed/33718107
http://dx.doi.org/10.3389/fonc.2020.600573
_version_ 1783663325295411200
author Thomas, Remy
Al-Khadairi, Ghaneya
Decock, Julie
author_facet Thomas, Remy
Al-Khadairi, Ghaneya
Decock, Julie
author_sort Thomas, Remy
collection PubMed
description Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the current superheroes of immunotherapy, unleashing a patient’s own immune cells to kill tumors and revolutionizing cancer treatment in a variety of cancers. Although breast cancer was historically believed to be immunologically silent, treatment with immune checkpoint inhibitors has been shown to induce modest responses in metastatic breast cancer. Given the inherent heterogeneity of breast tumors, this raised the question whether certain breast tumors might benefit more from immune-based interventions and which cancer cell-intrinsic and/or microenvironmental factors define the likelihood of inducing a potent and durable anti-tumor immune response. In this review, we will focus on triple negative breast cancer as immunogenic breast cancer subtype, and specifically discuss the relevance of tumor mutational burden, the plethora and diversity of tumor infiltrating immune cells in addition to the immunoscore, the presence of immune checkpoint expression, and the microbiome in defining immune checkpoint blockade response. We will highlight the current immune checkpoint inhibitor treatment options, either as monotherapy or in combination with standard-of-care treatment modalities such as chemotherapy and targeted therapy. In addition, we will look into the potential of immunotherapy-based combination strategies using immune checkpoint inhibitors to enhance both innate and adaptive immune responses, or to establish a more immune favorable environment for cancer vaccines. Finally, the review will address the need for unambiguous predictive biomarkers as one of the main challenges of immune checkpoint blockade. To conclude, the potential of immune checkpoint blockade for triple negative breast cancer treatment could be enhanced by exploration of aforementioned factors and treatment strategies thereby providing promising future prospects.
format Online
Article
Text
id pubmed-7947906
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79479062021-03-12 Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects Thomas, Remy Al-Khadairi, Ghaneya Decock, Julie Front Oncol Oncology Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the current superheroes of immunotherapy, unleashing a patient’s own immune cells to kill tumors and revolutionizing cancer treatment in a variety of cancers. Although breast cancer was historically believed to be immunologically silent, treatment with immune checkpoint inhibitors has been shown to induce modest responses in metastatic breast cancer. Given the inherent heterogeneity of breast tumors, this raised the question whether certain breast tumors might benefit more from immune-based interventions and which cancer cell-intrinsic and/or microenvironmental factors define the likelihood of inducing a potent and durable anti-tumor immune response. In this review, we will focus on triple negative breast cancer as immunogenic breast cancer subtype, and specifically discuss the relevance of tumor mutational burden, the plethora and diversity of tumor infiltrating immune cells in addition to the immunoscore, the presence of immune checkpoint expression, and the microbiome in defining immune checkpoint blockade response. We will highlight the current immune checkpoint inhibitor treatment options, either as monotherapy or in combination with standard-of-care treatment modalities such as chemotherapy and targeted therapy. In addition, we will look into the potential of immunotherapy-based combination strategies using immune checkpoint inhibitors to enhance both innate and adaptive immune responses, or to establish a more immune favorable environment for cancer vaccines. Finally, the review will address the need for unambiguous predictive biomarkers as one of the main challenges of immune checkpoint blockade. To conclude, the potential of immune checkpoint blockade for triple negative breast cancer treatment could be enhanced by exploration of aforementioned factors and treatment strategies thereby providing promising future prospects. Frontiers Media S.A. 2021-02-25 /pmc/articles/PMC7947906/ /pubmed/33718107 http://dx.doi.org/10.3389/fonc.2020.600573 Text en Copyright © 2021 Thomas, Al-Khadairi and Decock http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Thomas, Remy
Al-Khadairi, Ghaneya
Decock, Julie
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
title Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
title_full Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
title_fullStr Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
title_full_unstemmed Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
title_short Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
title_sort immune checkpoint inhibitors in triple negative breast cancer treatment: promising future prospects
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947906/
https://www.ncbi.nlm.nih.gov/pubmed/33718107
http://dx.doi.org/10.3389/fonc.2020.600573
work_keys_str_mv AT thomasremy immunecheckpointinhibitorsintriplenegativebreastcancertreatmentpromisingfutureprospects
AT alkhadairighaneya immunecheckpointinhibitorsintriplenegativebreastcancertreatmentpromisingfutureprospects
AT decockjulie immunecheckpointinhibitorsintriplenegativebreastcancertreatmentpromisingfutureprospects